---
authors:
- Sonoda, Kento
- Saguil, Aaron
category: Clinical Review
clinical_significance: High
external_resources:
- title: PubMed Entry
  type: reference
  url: https://pubmed.ncbi.nlm.nih.gov/35839371/
file_path: 2022/07/dpp-4-inhibitors-glp-1-receptor-agonists-and-sglt-2-inhibito.md
issue: '1'
keywords:
- Diabetes Mellitus, Type 2
- Humans
- Glucagon-Like Peptide-1 Receptor Agonists
- Cardiovascular Diseases
- Diabetes
- Dipeptidyl-Peptidase IV Inhibitors
- Sodium-Glucose Transporter 2 Inhibitors
- Hypoglycemic Agents
last_updated: '2025-07-30'
mesh_terms:
- Cardiovascular Diseases
- Diabetes Mellitus, Type 2
- Dipeptidyl-Peptidase IV Inhibitors
- Humans
- Hypoglycemic Agents
- Sodium-Glucose Transporter 2 Inhibitors
- Glucagon-Like Peptide-1 Receptor Agonists
original_format: PubMed
pages: 24-25
patient_population: Adults
peer_reviewed: true
pmid: '35839371'
processed_date: '2025-07-30'
publication_date: '2022-07-01'
pubmed_enriched: true
pubmed_enriched_date: '2025-08-09'
reading_time_minutes: 5
source: American family physician
specialty:
- Family Medicine
status: processed
tags:
- editorial
- family-practice
- clinical-medicine
- pubmed-enhanced
title: DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People
  With Cardiovascular Disease.
topics:
- Diabetes Mellitus
- Endocrinology
- Family Medicine
- Metabolic Disorders
volume: '106'
publication_types: &id001
- Journal Article
- Comment
pubmed_content_enriched: true
pubmed_full_data:
  pmid: '35839371'
  title: DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People
    With Cardiovascular Disease.
  authors:
  - last_name: Sonoda
    fore_name: Kento
    initials: K
    affiliation: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  - last_name: Saguil
    fore_name: Aaron
    initials: A
    affiliation: Brooke Army Medical Center, Fort Sam Houston, Texas.
  journal_info:
    title: American family physician
    iso_abbreviation: Am Fam Physician
    volume: '106'
    issue: '1'
  publication_info:
    year: '2022'
    month: '07'
    full_date: '2022-07-01'
  article_ids: {}
  mesh_terms:
  - descriptor: Cardiovascular Diseases
    major_topic: true
    qualifiers:
    - qualifier: drug therapy
      major_topic: false
    - qualifier: prevention & control
      major_topic: false
  - descriptor: Diabetes Mellitus, Type 2
    major_topic: true
    qualifiers:
    - qualifier: drug therapy
      major_topic: false
  - descriptor: Dipeptidyl-Peptidase IV Inhibitors
    major_topic: true
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Humans
    major_topic: false
  - descriptor: Hypoglycemic Agents
    major_topic: false
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Sodium-Glucose Transporter 2 Inhibitors
    major_topic: true
    qualifiers:
    - qualifier: therapeutic use
      major_topic: false
  - descriptor: Glucagon-Like Peptide-1 Receptor Agonists
    major_topic: false
  publication_types: *id001
related_articles:
- pmid: '35839371'
  title: DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People
    With Cardiovascular Disease.
  authors:
  - name: Sonoda K MD, AAHIVS
    authtype: Author
    clusterid: ''
  - name: Saguil A MD, MPH, FAAFP
    authtype: Author
    clusterid: ''
  source: Am Fam Physician
  pubdate: 2022 Jul
- pmid: '30676706'
  title: '[Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor
    agonists and SGLT-2 inhibitors].'
  authors:
  - name: Verburg AFE
    authtype: Author
    clusterid: ''
  - name: van den Donk M
    authtype: Author
    clusterid: ''
  - name: Wiersma T
    authtype: Author
    clusterid: ''
  source: Ned Tijdschr Geneeskd
  pubdate: 2019 Jan 14
- pmid: '31902326'
  title: Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering
    Drugs Added to Metformin in Type 2 Diabetes Mellitus.
  authors:
  - name: Raparelli V
    authtype: Author
    clusterid: ''
  - name: Elharram M
    authtype: Author
    clusterid: ''
  - name: Moura CS
    authtype: Author
    clusterid: ''
  - name: Abrahamowicz M
    authtype: Author
    clusterid: ''
  - name: Bernatsky S
    authtype: Author
    clusterid: ''
  - name: Behlouli H
    authtype: Author
    clusterid: ''
  - name: Pilote L
    authtype: Author
    clusterid: ''
  source: J Am Heart Assoc
  pubdate: 2020 Jan 7
- pmid: '31855074'
  title: 'Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2
    inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor
    agonists: proportional hazards analysis by deep neural network based machine learning.'
  authors:
  - name: Yamada T
    authtype: Author
    clusterid: ''
  - name: Iwasaki K
    authtype: Author
    clusterid: ''
  - name: Maedera S
    authtype: Author
    clusterid: ''
  - name: Ito K
    authtype: Author
    clusterid: ''
  - name: Takeshima T
    authtype: Author
    clusterid: ''
  - name: Noma H
    authtype: Author
    clusterid: ''
  - name: Shojima N
    authtype: Author
    clusterid: ''
  source: Curr Med Res Opin
  pubdate: 2020 Mar
- pmid: '38925801'
  title: 'SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk
    of hyperkalemia among people with type 2 diabetes in clinical practice: population
    based cohort study.'
  authors:
  - name: Fu EL
    authtype: Author
    clusterid: ''
  - name: Wexler DJ
    authtype: Author
    clusterid: ''
  - name: Cromer SJ
    authtype: Author
    clusterid: ''
  - name: Bykov K
    authtype: Author
    clusterid: ''
  - name: Paik JM
    authtype: Author
    clusterid: ''
  - name: Patorno E
    authtype: Author
    clusterid: ''
  source: BMJ
  pubdate: 2024 Jun 26
---

# DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People With Cardiovascular Disease.

**Authors:** Sonoda, Kento, Saguil, Aaron

**Published in:** American family physician | Vol. 106, No. 1 | 2022-07-01

**Links:** [PubMed](https://pubmed.ncbi.nlm.nih.gov/35839371/)

## Clinical Information

**Population:** Adults | **Clinical Significance:** High

## Topics & Specialties

**Specialties:** Family Medicine

**Topics:** Diabetes Mellitus, Endocrinology, Family Medicine, Metabolic Disorders

## MeSH Terms

Cardiovascular Diseases, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Humans, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists

## Article Content

*Full article content to be extracted and formatted from source material.*

## Additional Resources

- [PubMed Entry](https://pubmed.ncbi.nlm.nih.gov/35839371/) (reference)

---

*Processed: 2025-07-30* | *PubMed Enhanced: 2025-07-30*
